Colchicine for Stroke Prevention (CHANCE-3 Trial) 📍 Study Type: Randomized, placebo-controlled trial🏥 Setting: 244 hospitals in China👥 Participants: 8,343 patients (age ≥40) with minor/moderate ischemic stroke or TIA & hs-CRP ≥2 mg/L Intervention vs. Control 💊 Colchicine Group (n=4,176)• 0.5 … Read More
Neurology
POST-TNK Trial: Intra-Arterial Tenecteplase in Acute Stroke
Visual Summary of POST-TNK Trial Objective:To evaluate the efficacy and safety of intra-arterial tenecteplase in patients with large vessel occlusion stroke achieving near-complete to complete reperfusion after EVT. Design & Participants: Interventions:Patients were randomized into two groups: Primary Outcome:Freedom from … Read More
CAMMS223 Trial: Alemtuzumab vs. Interferon B1a in Early Multiple Sclerosis
Published in the New England Journal of Medicine (2008), the CAMMS223 trial provides critical insights into the efficacy of Alemtuzumab compared to Interferon Beta-1a in patients with early, relapsing-remitting multiple sclerosis (RRMS). This phase 2, randomized, blinded study highlights the … Read More
ATTENTION Trial: Endovascular Treatment for Acute Basilar-Artery Occlusion
Published in the New England Journal of Medicine (2022), the ATTENTION Trial is a landmark study exploring the efficacy and safety of endovascular treatment (EVT) for patients with acute basilar artery occlusion (BAO). Here’s an in-depth look at the findings … Read More
MS-SMART Trial: Neuroprotection in Multiple Sclerosis
MS-SMART Trial: Evaluating Neuroprotection in Secondary Progressive Multiple Sclerosis Secondary progressive multiple sclerosis (SPMS) remains one of the most challenging forms of MS to treat, as no effective therapies currently exist to halt disease progression. The MS-SMART trial (2020) was … Read More
ATTEST-2 Trial: Tenecteplase vs. Alteplase for Stroke
ATTEST-2 Trial — Comparing Tenecteplase and Alteplase for Acute Stroke Management Introduction In recent years, the quest for optimal treatments for acute ischemic stroke has intensified, with the goal of improving outcomes and accessibility of care. The ATTEST-2 trial, published … Read More
TRAIN Trial: Transfusion Strategy in Acute Brain Injury
Understanding the TRAIN Trial: Transfusion Strategies in Patients with Acute Brain Injury In 2024, a groundbreaking study called the TRAIN Trial explored the impact of different transfusion strategies in patients suffering from acute brain injuries. This large, pragmatic, phase 3 … Read More
ARCADIA Trial: Apixaban After Cryptogenic Stroke
The ARCADIA trial, published in JAMA in 2024, compared the efficacy of apixaban versus aspirin in preventing recurrent strokes in patients with cryptogenic stroke and atrial cardiopathy. Key Findings: Conclusion: In patients with cryptogenic stroke and evidence of atrial cardiopathy … Read More
LIXIPARK Trial: Lixisenatide in Early Parkinson’s Disease
Objective: To evaluate the effect of lixisenatide, versus placebo, administered as add-on therapy with the usual antiparkinsonian treatment, on the progression of motor disability in patients with early Parkinson’s Disease (PD) to assess its potential “disease-modifying” effect. Inclusion Criteria: Exclusion … Read More
RESCUE BT2 Trial: Tirofiban for Acute Ischemic Stroke
Summary of the RESCUE BT2 Trial: Tirofiban in Acute Ischemic Stroke Background: Methods: Inclusion criteria: Results: Conclusions: Key Takeaways: Source